- Previous Close
17.60 - Open
17.62 - Bid 17.69 x 500
- Ask 17.80 x 200
- Day's Range
17.44 - 18.10 - 52 Week Range
10.75 - 18.17 - Volume
133,817 - Avg. Volume
132,426 - Market Cap (intraday)
661.037M - Beta (5Y Monthly) -0.25
- PE Ratio (TTM)
5.88 - EPS (TTM)
3.02 - Earnings Date Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.50
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
www.entradatx.comRecent News: TRDA
View More
Performance Overview: TRDA
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRDA
View MoreValuation Measures
Market Cap
660.48M
Enterprise Value
255.18M
Trailing P/E
5.88
Forward P/E
3.33k
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.54
Price/Book (mrq)
1.54
Enterprise Value/Revenue
1.07
Enterprise Value/EBITDA
2.63
Financial Highlights
Profitability and Income Statement
Profit Margin
43.63%
Return on Assets (ttm)
10.86%
Return on Equity (ttm)
32.80%
Revenue (ttm)
239.4M
Net Income Avi to Common (ttm)
104.44M
Diluted EPS (ttm)
3.02
Balance Sheet and Cash Flow
Total Cash (mrq)
469.75M
Total Debt/Equity (mrq)
14.99%
Levered Free Cash Flow (ttm)
25.43M
Research Analysis: TRDA
View MoreCompany Insights: TRDA
TRDA does not have Company Insights
Research Reports: TRDA
View MoreDaily – Vickers Top Buyers & Sellers for 05/17/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/27/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/22/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.